TOKYO, May 27 (Pulse News Wire) – Medicinova,inc. (4875.T) announced today that the final patient visit (last patient last visit, LPLV) was completed for its Phase 2 clinical trial evaluating MN-001 (Tap) as a treatment for high triglyceride levels and non-alcoholic fatty liver disease (NAFLD) associated with Type 2 diabetes (T2DM).
The multi-center, randomized, double-blind, placebo-controlled study involved patients being randomly assigned in a 1:1 ratio to receive either MN-001 at 500 mg per day or placebo for 24 weeks. Primary endpoints included changes in liver fat content measured by controlled attenuation parameter (CAP) score and fasting serum triglycerides from baseline at week 24. Secondary endpoints focused on safety, tolerability, and lipid profile changes such as HDL-C, LDL-C, and total cholesterol.
Top-line data from the trial is expected to be available in the third quarter of 2026. The company noted there would be no impact on its consolidated performance for the fiscal year ending December 2026, but it will promptly disclose any significant developments going forward. MN-001 is a novel oral compound with multiple mechanisms of action, including antagonism of Leukotriene Juyou Tai, phosphodiesterase inhibition, and suppression of inflammatory pathways through the 5-lipoxygenase pathway.
Previous clinical trials showed MN-001 reduces blood triglycerides and improves overall lipid profiles in patients with NAFLD and non-alcoholic steatohepatitis (NASH).
🟢 Confidence: High AI-translated content.